This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

Schizophrenia International Research Society
April 3rd – 7th 2024, Florence, Italy
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Bipolar Disorder
Schizophrenia
PRESENTATION
Long-Term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon1, René S. Kahn2, Christina Arevalo3, Martin Dunbar3, David McDonnell4, Christoph U. Correll5-7